Bottom line
Medicare coverage of GLP-1 medications is one of the most consequential — and confusing — insurance questions in 2026. The short version:
- **Medicare Part D has historically excluded coverage of
drugs prescribed for weight loss.** This exclusion has been in statute since Part D was created in 2003.
- Medicare does cover GLP-1s for type 2 diabetes. Ozempic
and Mounjaro are covered by most Part D plans when prescribed for diabetes with appropriate documentation.
- The Treat and Reduce Obesity Act and related legislation
have been introduced multiple times to lift the Part D weight-loss drug exclusion. As of early 2026, this legislation has not passed, though political momentum has increased.
- The SELECT cardiovascular indication for Wegovy has
created a new coverage pathway — CMS is evaluating whether Wegovy prescribed for cardiovascular risk reduction (distinct from weight loss) can be covered under Part D.
- Medicare Advantage plans have more flexibility and some
have begun covering anti-obesity medications as a supplemental benefit.
- **Manufacturer savings programs (LillyDirect, NovoCare)
cannot be used by Medicare beneficiaries** — federal law prohibits manufacturer copay assistance for federal program beneficiaries.
For Medicare beneficiaries with obesity and no diabetes, the path to GLP-1 access in 2026 is difficult but not impossible. Here's the detailed landscape.
Why Medicare excludes weight-loss drugs
The Medicare Modernization Act of 2003, which created Part D (outpatient prescription drug coverage), included a specific statutory exclusion for "agents when used for anorexia, weight loss, or weight gain." This exclusion was written at a time when anti-obesity medications were primarily appetite suppressants with limited efficacy and significant safety concerns (fen-phen had been withdrawn in 1997).
The exclusion has persisted despite the dramatic evolution of obesity treatment. It applies to any drug prescribed for the indication of weight loss or weight management — regardless of the drug's efficacy, safety profile, or clinical value.
This means:
- Wegovy (semaglutide for weight management): not covered
under standard Part D
- Zepbound (tirzepatide for weight management): not covered
under standard Part D
- Saxenda (liraglutide for weight management): not covered
under standard Part D
The exclusion applies to the indication, not the molecule. The same semaglutide molecule is covered when prescribed as Ozempic for diabetes but excluded when prescribed as Wegovy for weight management.
What IS covered for Medicare beneficiaries
GLP-1s for type 2 diabetes:
- Ozempic (semaglutide): covered by most Part D formularies
with prior authorization. Typical copay: $25-100/month depending on plan tier and coverage phase.
- Mounjaro (tirzepatide): covered by a growing number of
Part D formularies. Coverage is less universal than Ozempic but expanding.
- Rybelsus (oral semaglutide): covered for diabetes on
most formularies.
- Trulicity (dulaglutide): broadly covered.
If you have type 2 diabetes and obesity, you can access GLP-1 therapy through the diabetes indication. The weight loss is a clinically expected effect of the diabetes treatment — the drug doesn't know which indication is on the prescription.
Intensive Behavioral Therapy (IBT) for obesity: Medicare Part B covers IBT for obesity — a program of counseling visits with a primary care provider for patients with BMI ≥30. This is separate from medication coverage and can be valuable as a complement to other approaches.
Bariatric surgery: Medicare covers bariatric surgery for beneficiaries with BMI ≥35 and a weight-related comorbidity (or BMI ≥40 without). This is one of the few covered weight-loss interventions for Medicare patients without diabetes.
The cardiovascular pathway
The 2024 FDA approval of Wegovy for cardiovascular risk reduction created a potentially transformative argument: if Wegovy is prescribed not for weight loss but for cardiovascular risk reduction in patients with established ASCVD and BMI ≥27, does the Part D weight-loss exclusion still apply?
The legal argument: the statutory exclusion applies to drugs "when used for weight loss." Wegovy prescribed for cardiovascular risk reduction is not being used for weight loss — it's being used to reduce heart attacks and strokes, which happens to also cause weight loss.
Current status (April 2026):
- CMS has not issued definitive guidance on whether the
cardiovascular indication exempts Wegovy from the Part D exclusion
- Some Part D plan sponsors have begun covering Wegovy under
the cardiovascular indication on a case-by-case basis, requiring documentation of established ASCVD
- Appeals of coverage denials citing the cardiovascular
indication have had mixed success
- Several advocacy organizations and medical societies have
submitted formal requests to CMS for clarification
This pathway is real but uncertain. If your prescriber submits a prior authorization for Wegovy citing the cardiovascular indication (not the weight-management indication) and you have documented ASCVD, it is worth attempting — but expect a possible denial and be prepared to appeal.
Medicare Advantage (Part C)
Medicare Advantage (MA) plans — privately administered alternatives to traditional Medicare — have more flexibility to offer supplemental benefits beyond what traditional Medicare covers. Some MA plans have begun offering anti-obesity medication coverage as a supplemental benefit, particularly for beneficiaries with obesity-related comorbidities.
As of 2026:
- A small but growing number of MA plans include GLP-1
coverage for weight management
- Coverage varies by plan, region, and year — it can change
at annual enrollment
- Prior authorization requirements are typically stringent
- The coverage is supplemental, meaning the plan is choosing
to offer it (and paying for it), not that CMS requires it
If you're a Medicare beneficiary with obesity and are choosing between MA plans during open enrollment, GLP-1 coverage is now a factor worth evaluating.
Cash-pay options for Medicare beneficiaries
Because the Part D exclusion blocks drug coverage and federal law prohibits manufacturer copay assistance (LillyDirect and NovoCare cannot enroll Medicare beneficiaries), cash-pay options are limited:
Full cash price at a retail pharmacy:
- Wegovy: ~$1,300-1,400/month
- Zepbound: ~$1,000-1,100/month
These prices are prohibitive for most Medicare beneficiaries on fixed incomes.
Patient assistance programs (PAPs): Both Novo Nordisk and Eli Lilly operate need-based patient assistance programs that can provide free or reduced-cost medication to patients who meet income requirements. These are distinct from the savings card programs and are available to Medicare beneficiaries. Eligibility criteria typically include income below 400% of the federal poverty level.
- Novo Nordisk PAP: covers Wegovy for eligible patients
- Lilly Cares: covers Zepbound and Mounjaro for eligible
patients
Application requires income documentation and prescriber involvement. Processing can take 2-4 weeks.
Clinical trials: Medicare beneficiaries may be eligible for clinical trials studying GLP-1 medications for new indications, where the study drug is provided free. Eligibility is narrow and trial-specific, but worth exploring through clinicaltrials.gov.
What legislation could change
The Treat and Reduce Obesity Act (TROA) has been introduced in multiple Congressional sessions. If passed, it would:
- Remove the Part D exclusion for FDA-approved anti-obesity
medications
- Expand Medicare coverage of IBT for obesity to include
additional provider types (dietitians, health coaches)
- Potentially cover obesity counseling through Part B
The CBO (Congressional Budget Office) has scored various versions of TROA at $20-40+ billion over 10 years — the high cost is the primary political obstacle. Some versions propose phased implementation or cost-sharing requirements to reduce the score.
Political momentum has increased as GLP-1s have become more visible and as the cardiovascular and metabolic benefits have accumulated. Multiple medical societies (AMA, Obesity Society, ADA, AHA) have endorsed lifting the exclusion. Bipartisan support exists but is not yet sufficient for passage.
As of April 2026, TROA or a similar bill has not passed. There is no guaranteed timeline.
What to do now
If you're a Medicare beneficiary with obesity:
1. If you have type 2 diabetes: Get a GLP-1 prescribed under the diabetes indication. This is the most reliable current pathway. Ozempic and Mounjaro are the most commonly covered.
2. If you have established cardiovascular disease + BMI ≥27: Ask your prescriber to submit a prior authorization for Wegovy under the cardiovascular risk reduction indication. Be prepared for a denial and an appeal.
3. If you're choosing a Medicare Advantage plan: During open enrollment, check whether candidate plans offer anti-obesity medication as a supplemental benefit.
4. If you meet income requirements: Apply for manufacturer patient assistance programs (Novo Nordisk PAP, Lilly Cares).
5. If none of the above applies: Discuss alternative approaches with your prescriber — including IBT for obesity (covered by Part B), older anti-obesity medications (phentermine, which is inexpensive but excluded from Part D for the same reason), and bariatric surgery if BMI qualifies.
What this means for you
The Medicare GLP-1 coverage gap is one of the most significant health equity issues in obesity medicine today. The patients who would benefit most from these medications — older adults with obesity-related cardiovascular disease, diabetes risk, mobility limitations, and joint disease — are systematically excluded from the most effective treatments by a 2003 statute that predates the modern GLP-1 era.
If you're in this position, you're not alone, and you're not without options. The diabetes indication, the cardiovascular pathway, MA supplemental benefits, and patient assistance programs are all real paths. None is as clean as "your doctor prescribes it and insurance covers it," but they're the tools available while the legislative landscape catches up to the clinical science.